Últimas noticias sobre OmniAb (NASDAQ:OABI) Bolsa

OMNIAB INC

OmniAb

OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Las acciones en EE. UU. suben a mitad de jornada, lideradas por un crecimiento en energía. El Dow sube 200 pts y el petróleo repunta.

Wall Street en alza: Dow sube 200 puntos mientras el petróleo y el oro se mantienen firmes

OmniAb Inc

Monolithic Power Systems, Inc. ("MPS") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), a fabless global company that provides high-performance, semiconductor-based power electronics solutions, today announced updates to its financial guidance for the three months ending March 31, 2025.
The following table presents the updated financial guidance for the three months ending March 31, 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previously Announced on February 6, 2025</td>
<td>Updated as of March 20, 2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$610.0&nbsp;million to $630.0&nbsp;million</td>
<td>$630.0&nbsp;million to $640.0&nbsp;million</td>
</tr>
<tr>
<td>GAAP operating expenses</td>
<td>$180.2 million to $186.2 million</td>
<td>$184.9 million to $190.9 million</td>
</tr>
<tr>
<td>Non-GAAP (1) operating expenses</td>
<td>$126.9 million to $130.9&nbsp;million</td>
<td>$131.6 million to $135.6&nbsp;million</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

MPWR

Monolithic Power Systems Raises Q1 Revenue Guidance From $610M-$630M To $630M-$640M Vs $578.09M Est.

ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) shares are trading lower on Thursday. The company&nbsp;reported fiscal&nbsp;fourth-quarter revenue of 22.78 billion&nbsp;Chinese Yuan, representing<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44409992/zeekr-group-reports-fourth-quarter-and-full-year-2024-unaudited-financial-results" rel="noreferrer noopener"> an increase of&nbsp;39.2% year-on-year</a>.
In USD terms, revenue of $3.12 billion missed the&nbsp;analyst consensus estimate of&nbsp;$3.18 billion.
Total vehicle deliveries were 79,250&nbsp;units for the&nbsp;fourth quarter of 2024, up&nbsp;99.8% Y/Y.
Also, the company delivered 31,277&nbsp;vehicles in&nbsp;February 2025 following the acquisition completion of Lynk &amp; Co. This included 14,039 Zeekr brand vehicles and 17,238 Lynk &amp; Co brand vehicles.
Vehicle sales&nbsp;were&nbsp;19.30 billion&nbsp;Chinese Yuan&nbsp;($2.64 billion) for the quarter, representing an increase of&nbsp;82.2%&nbsp;Y/Y aided by an increase in new product delivery volume.
The vehicle margin was&nbsp;17.3%, up from&nbsp;15.3%&nbsp;in the prior year quarter, led by cost reduction.
Revenues from sales of batteries and other components were&nbsp;1.93 billion&nbsp;Chinese Yuan&nbsp;($264.5 million) for the quarter, representing a decline of&nbsp;52.2%&nbsp;Y/Y, owing to lower sales volume and unit price of battery packs and electric drives.
Revenues from research and development services and other services were&nbsp;1.55 billion Chinese Yuan&nbsp;($211.7&nbsp;million) for the quarter, representing a decrease&nbsp; of&nbsp;10.5% Y/Y.
The gross margin expanded to&nbsp;19.0% for the quarter from&nbsp;14.2%&nbsp;a year ago.
The premium electric vehicle company's adjusted net loss per ADS came in at 3.56 Chinese Yuan. In USD terms, adjusted EPS loss of&nbsp;49 cents&nbsp;missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus loss estimate of&nbsp;4 cents</a>.
As of&nbsp;December 31, 2024, cash and cash equivalents and restricted cash&nbsp;stood at 8.96 billion Chinese Yuan ($1.23 billion).
Zeekr Group disclosed it has completed strategic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44413069/zeekr-group-announced-unaudited-pro-forma-condensed-combined-financial-information" rel="noreferrer noopener">transactions within the </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44413069/zeekr-group-announced-unaudited-pro-forma-condensed-combined-financial-information" rel="noreferrer noopener">Geely group</a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44413069/zeekr-group-announced-unaudited-pro-forma-condensed-combined-financial-information" rel="noreferrer noopener">.</a>
It has acquired a 51% stake in LYNK &amp; CO. Zhejiang Zeekr purchased 30% from Volvo Car (China) for 5.4 billion Chinese Yuan ($740 million) and 20% from Geely Holding for 3.6 billion Chinese Yuan ($493 million), alongside a 367 million Chinese Yuan ($50 million) capital injection. The deal closed on February 14, 2025.
Investors can gain exposure to the stock via&nbsp;iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>).
Price Action: ZK shares are down 10.4% at $25.30 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44416435/oracle-expands-microsoft-partnership-enhances-cloud-offerings-and-secures-major-deals" target="_blank" rel="noreferrer noopener">Oracle Expands Microsoft Partnership, Enhances Cloud Offerings</a></li>
</ul>
Image Credits &#8211; Shutterstock.

Mid Cap

Movers

IDRV

Why Is ZEEKR Stock Plunging Today?

Bernstein analyst Firoz Valliji initiates coverage on HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Market Perform rating and announces Price Target of $693.

Price Target

Initiation

Analyst Ratings

HUBS

Bernstein Initiates Coverage On HubSpot with Market Perform Rating, Announces Price Target of $693

Consumer confidence <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44337983/horrific-report-economists-warn-consumer-confidence-collapse-signals-economic-trouble">fell sharply</a> in March as Americans grappled with historically high inflation expectations and uncertainties surrounding tariffs. But, Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) CEO Rick Cardenas said Thursday the company has seen resilience in consumer spending when it comes <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44417951/darden-restaurants-expands-uber-delivery-option-to-cheddars-following-successful-rollout-at-olive-garden">to dining out. </a>
What To Know: Darden Restaurants released its third-quarter <a href="https://www.benzinga.com/25/03/44416210/darden-restaurants-posts-mixed-q3-earnings-stock-slides">earnings report</a> on Thursday morning and posted profitable sales growth. The company also issued fiscal 2025 sales guidance above analysts' expectations even as consumers feel the pinch from years of inflation and grow concerned about the future of the economy.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/03/44418531/alphabets-waymo-to-begin-mapping-san-francisco-airport">Alphabet&#8217;s Waymo Receives Mapping Permit For San Francisco Airport In A Step Toward SFO Robotaxi Service&nbsp;</a>
Cardenas gave some insight into the company's relatively rosy outlook in what he called a "challenging environment."
On the company's earnings call with analysts, Cardenas said all of the company's segments grew in total sales and profit margins, despite the drop in consumer confidence. 
"People, even if they say they're feeling less optimistic, we haven't seen a huge correlation between that and dining out. So changes in consumer sentiment haven't necessarily translated to material changes in consumer spending," Cardenas said.&nbsp;
Consumers are looking for value for their money, Cardenas said, and noted a "little bit more pullback in guests with incomes below $50,000.&nbsp;
Darden's fiscal year sales guidance of $12.1 billion across all of its brands shows the company's confidence in consumers continuing to spend on dining out in the coming months. 
"I think as long as incomes are going up and outpacing inflation, I think they're likely to keep spending," Cardenas said.
Darden Restaurants includes Olive Garden, LongHorn Steakhouse, Yard House, Ruth&#8217;s Chris Steak House, Cheddar's Scratch Kitchen, The Capital Grille, Chuy&#8217;s, Seasons 52, Eddie V&#8217;s and Bahama Breeze.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44367584/black-swan-hedge-fund-posts-4000-profits-during-covid-19-market-crash-heres-how">Black Swan&#8217; Hedge Fund Posts 4,000% Profits During COVID-19 Market Crash: Here&#8217;s How</a></li>
</ul>
Photo: Shutterstock

Restaurants

Economics

Darden Restaurants CEO Says Consumers 'Likely To Keep Spending' Despite 'Challenging Environment'

Scotiabank analyst Louise Chen maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform and lowers the price target from $105 to $80.

SRPT

Scotiabank Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $80

BTIG analyst Marie Thibault initiates coverage on Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy rating and announces Price Target of $12.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

BTIG Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $12

On Thursday, Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
The company was developing a treatment for advanced, unresectable or metastatic gastric and <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">gastroesophageal junction cancers</a>.
The decision came due to disappointing data from the dose escalation and expansion stages of <a href="https://www.benzinga.com/pressreleases/25/03/n44414417/elevation-oncology-to-discontinue-development-of-eo-3021-advancing-eo-1022-while-evaluating-strate" target="_blank" rel="noreferrer noopener">Elevation Oncology&#8217;s Phase 1 trial</a>.
Treatment with EO-3021 as monotherapy demonstrated an objective response rate of 22.2% (1 confirmed complete response and 7 confirmed partial responses) and a disease control rate of 72.2% among 36 evaluable patients with gastric or GEJ cancer and Claudin 18.2 in ≥20% of tumor cells at IHC 2+/3+.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42793169/penny-stock-elevation-oncology-positioned-for-high-growth-in-antibody-drug-conjugates-market-analyst-sees-favorable-risk-to-reward-ratio" rel="noreferrer noopener">Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise</a>
In the safety analysis of all enrolled patients (n=85), treatment with EO-3021 was observed to be generally well-tolerated.
Treatment with EO-3021 did not meet the company&#8217;s &#8220;bar for success,&#8221; said Elevation Oncology CEO Joseph Ferra.
Elevation Oncology will continue to advance EO-1022, a HER3 ADC for patients with HER3-expressing solid tumors. The company plans to file an Investigational New Drug (IND) application in 2026.
In parallel, the company is initiating a process to evaluate strategic options to maximize shareholder value.
Elevation Oncology is implementing a workforce reduction of approximately 70%. The layoffs will result in total cash payments and costs of approximately $3 million.
As part of this reduction, Elevation Oncology&#8217;s Chief Medical Officer, Valerie Malyvanh Jansen, will step down, effective March 31.
Elevation Oncology expects that its cash, cash equivalents, and marketable securities of $93.2 million as of Dec. 31, will be sufficient to fund its operations into the second half of 2026.
Price Action: ELEV stock is down 47.1% at 25 cents at the last check Thursday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415537/shoe-carnival-q4-earnings-sales-miss-eps-beat-new-shoe-station-strategy-gloomy-outlook-and-more" target="_blank" rel="noreferrer noopener">Shoe Carnival Q4 Earnings: Sales Miss &amp; EPS Beat, New Shoe Station Strategy, Gloomy Outlook, And More</a></li>
</ul>

Biotech

Health Care

General

ELEV

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) has outperformed the market over the past 15 years by 8.65% on an annualized basis producing an average annual return of 19.8%. Currently, Costco Wholesale has a market capitalization of $400.77 billion. 
Buying $100 In COST: If an investor had bought $100 of COST stock 15 years ago, it would be worth $1,504.20 today based on a price of $903.27 for COST at the time of writing.
<h3>Costco Wholesale's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742485513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COST

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

U.S. President Donald Trump called on Congress to pass stablecoin legislation during his address at the Blockworks Digital Asset Summit in New York City, emphasizing the need for clear rules to foster <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44415405/donald-trump-reportedly-making-big-announcement-for-next-steps-in-crypto-policy-at-digital-asset-summit-on-thursday">innovation in the cryptocurrency sector. </a>
What Happened: Speaking to an audience of crypto industry leaders, Trump highlighted the potential of stablecoins to enhance the U.S. financial system and maintain the dollar's global dominance, marking his first address at a crypto conference as a sitting president.
The summit, held at 10:40 AM ET, follows a series of <a href="https://www.benzinga.com/government/regulations/25/03/44195822/what-will-trump-say-at-white-house-crypto-summit-bets-favor-ai-xrp-solana">pro-crypto actions</a> by the Trump administration, reflecting a shift from previous regulatory hostility toward digital assets.
Trump underscored the importance of a legal framework for stablecoins, which he believes will enable institutions to invest and innovate freely. 
"I've also called on Congress to pass landmark legislation creating simple, common-sense rules for stable coins and market structure," he stated, framing the move as a critical step in a broader technological revolution. 
He further emphasized the potential benefits, saying, "With the right legal framework, institutions large and small will be liberated to invest, innovate, and take part in one of the most exciting technological revolutions in modern history."
The push for <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44419298/why-the-future-of-stablecoins-like-usdt-usdc-looks-bright-report#:~:text=A%20stablecoin%2Dnative%20economy%20could,replacing%20fiat%20in%20mainstream%20finance.">stablecoin legislation</a> aligns with Trump's vision to position the U.S. as the global leader in crypto, a goal he reiterated by pledging to make America "the undisputed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) superpower and the crypto capital of the world."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44414660/coinbase-sold-12652-eth-according-to-standard-chartered-analysis">Coinbase Sold 12,652 ETH, According To Standard Chartered Analysis</a>
Why It Matters: The address comes on the heels of Trump's recent crypto initiatives, including the White House Digital Asset Summit two weeks prior, led by AI and crypto czar David Sachs, and an executive order signed the same week establishing the <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44197287/us-to-conduct-full-audit-of-bitcoin-holdings-following-strategic-reserve-executive-order">Strategic Bitcoin Reserve</a> and U.S. Digital Asset Stockpile. 
Trump criticized the Biden administration's handling of crypto assets, noting, "Biden got a fraction of their value," in reference to the government's past sales of seized Bitcoin. 
He also highlighted the termination of Operation Choke Point 2.0, a policy he described as "a form of lawfare through government weaponization," which had restricted banking access for crypto firms. 
The event, attended by figures like Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) CEO Brad Garlinghouse and Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman Michael Saylor, points toward a growing government engagement with the crypto industry.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44407461/recession-would-be-a-big-catalyst-for-bitcoin-blackrocks-head-of-digital-assets-says">Recession Would Be &#8216;A Big Catalyst For Bitcoin,&#8217; BlackRock&#8217;s Head Of Digital Assets Says</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$XRP

MSTR

Donald Trump Calls For Stablecoin Legislation, Lauds Bitcoin Reserve: 'Biden Got A Fraction Of Their Value'

Bakkt Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) shares are trading higher by 25% to $11.64 during Thursday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/03/b44406533/bakkt-reports-fourth-quarter-and-full-year-2024-results">strategic partnership</a> with Distributed Technologies.
What Happened: Bakkt formed a strategic partnership with Distributed Technologies Research (DTR) to integrate its regulated crypto trading and brokerage platform with DTR's stablecoin payments technology, pending regulatory approval.
This collaboration aims to enable stablecoin transactions for Bakkt's customers, potentially opening new revenue opportunities and expanding its reach into the cross-border payments sector.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44418891/us-home-sales-jump-in-february-median-price-nears-400000-next-big-move-could-shock-everyone-analysts-say">US Home Sales Jump In February, Median Price Nears $400,000: &#8216;Next Big Move Could Shock Everyone,&#8217; Analysts Say</a>
What Else: Bakkt <a href="https://www.benzinga.com/pressreleases/25/03/b44406533/bakkt-reports-fourth-quarter-and-full-year-2024-results">appointed</a> Akshay Naheta as co-CEO alongside Andy Main. The company has also signed an agreement to sell Bakkt Trust to ICE for $1.5 million, reducing costs by $3.8 million annually.
Bakkt said the company is also exploring strategic alternatives for its Loyalty segment after Bank of America <a href="https://www.benzinga.com/news/25/03/44401169/why-bakkt-bkkt-stock-is-volatile-this-week">decided not to renew</a> its contract. Webull, Bakkt's top crypto revenue client, will end its contract in mid-2025. 
Despite these shifts, Bakkt saw a record fourth-quarter 2024 trading volume of $1.78 billion, aided by BakktX integration, improving scalability and market reach.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/03/44416782/trump-pressures-fed-to-cut-interest-rates-as-liberation-day-in-america-looms">Trump Urges Fed To Cut Interest Rates As &#8216;Liberation Day In America&#8217; Looms</a>
<h2 class="wp-block-heading">How To Buy BKKT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bakkt&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BKKT has a 52-week high of $37.21 and a 52-week low of $5.57.

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Why Bakkt (BKKT) Stock Is Skyrocketing Today

Scotiabank analyst Greg Harrison maintains Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Sector Outperform and raises the price target from $30 to $34.

LQDA

Scotiabank Maintains Sector Outperform on Liquidia, Raises Price Target to $34

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) has released a research paper <a href="https://www.benzinga.com/pressreleases/25/03/b44413130/d-wave-introduces-quantum-blockchain-architecture-featuring-enhanced-security-and-efficiency-over-">presenting a new blockchain architecture</a> that capitalizes on the company&#8217;s quantum breakthrough. 
This advanced system integrates quantum computing with traditional blockchain processes, boosting both security and efficiency. The paper, titled &#8220;Blockchain with Proof of Quantum Work,&#8221; highlights how quantum methods can enhance blockchain technology.
The paper outlines a &#8220;proof of quantum&#8221; algorithm created by D-Wave, utilizing quantum computations to generate and verify blockchain hashes. 
Also Read: <a href="https://www.benzinga.com/general/health-care/25/03/44359600/hyperfine-nvidia-partner-to-make-brain-mris-more-affordable">Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable</a>
At present, blockchain systems depend on hashing, a mathematical function that protects transactions, along with &#8220;proof of work&#8221; algorithms that are highly energy-consuming. 
D-Wave&#8217;s findings propose that quantum computing could drastically lower the energy needed for these operations, potentially cutting energy usage by up to 1,000 times compared to conventional computing techniques, eventually reducing the environmental impact of blockchain technologies.
The company has also performed the inaugural demonstration of distributed quantum computing. This involved implementing the blockchain architecture across four cloud-based annealing quantum computers located in North America.
It represents the first instance of blockchain technology operating on a distributed quantum computing network.
The newly developed quantum-powered approach maps mathematical functions to complex spin glasses, simulated through D-Wave&#8217;s quantum systems, offering a new and more secure method of generating blockchain hashes. T
This quantum-based system is a departure from classical methods, enhancing the security of blockchain transactions and eliminating the need for classical computation in hash generation.
The technology can also benefit sectors such as supply chain management, healthcare, identity verification, and decentralized finance, beyond cryptocurrencies like Bitcoin. 
Price Action: QBTS shares traded lower by 6.23% at $9.94 at last check Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44419711/fartcoin-soars-13-in-a-day-outpacing-dogecoin-shiba-inu-is-a-return-to-all-time-highs-in-the-cards">Fartcoin Soars 13% In A Day Outpacing Dogecoin, Shiba Inu: Is A Return To All-Time Highs In The Cards?</a></li>
</ul>
Image: Shutterstock

QBTS

D-Wave Unveils New Blockchain Architecture To Slash Energy Usage

Scotiabank analyst John Zamparo maintains Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Sector Outperform and lowers the price target from C$85 to C$83.

TSX:ATD

Scotiabank Maintains Sector Outperform on Alimentation Couche-Tard, Lowers Price Target to C$83

HC Wainwright &amp; Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and maintains $34 price target.

Reiteration

RGNX

HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Caleres, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) shares are trading higher after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44412721/caleres-reports-fourth-quarter-full-year-results-and-provides-2025-outlook" rel="noreferrer noopener">reported&nbsp;fourth-quarter results</a>.
Revenues fell 8.3% year over year to $639.2&nbsp;million, missing&nbsp;the analyst consensus of&nbsp;$653.86 million.
Famous Footwear sales fell&nbsp;9.6%&nbsp;Y/Y, with comparable store sales down 2.9%. Brand Portfolio sales decreased&nbsp;7.2%&nbsp;in the quarter.
&#8220;Famous Footwear&#8217;s business softened in the quarter, but we maximized key selling periods. We invested to support our long-term growth while continuing to evolve our supply chain and further mitigate the impact of additional tariffs,&#8221; said Jay Schmidt, president and chief executive officer.
The company&#8217;s gross margin rate contracted 80&nbsp;basis points year over year to&nbsp;43.0% and adjusted EBITDA fell to $29.0 million.
Adjusted EPS of&nbsp;33 cents&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus of&nbsp;24 cents</a>.
In 2024, Caleres returned $74.7 million in cash to shareholders through dividends and share repurchases. Borrowings under the revolving credit facility totaled $219.5 million at the end of the period.
&#8220;As we look forward to 2025 and the macroeconomic environment with persistent inflation and newer tariffs, we believe it is prudent to take a conservative view for the year,&#8221; added Schmidt.
Outlook: The company expects FY25 net sales to decline by&nbsp;1% to up 1%&nbsp;and EPS of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$2.80 &#8211; $3.20&nbsp;(consensus&nbsp;$3.21)</a>.
For the first quarter, Caleres expects sales to decline 5% – 6% and EPS of&nbsp;$0.35 &#8211; $0.40&nbsp;vs.&nbsp;consensus of $0.87.
Caleres said it currently expects&nbsp;75%&nbsp;of its Brand Portfolio, and an even greater percentage of Lead Brands&#8217; sourcing to be outside of China by the second half of 2025.
Last month, the company inked a deal to acquire Stuart Weitzman&nbsp;from&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43820457/footwear-firm-calere-steps-into-luxury-105-million-stuart-weitzman-deal-set-for-2025-close" rel="noreferrer noopener">Tapestry </a><a target="_blank" href="https://www.benzinga.com/25/02/43820457/footwear-firm-calere-steps-into-luxury-105-million-stuart-weitzman-deal-set-for-2025-close" rel="noreferrer noopener">for $105 million</a>.&nbsp;The guidance excludes this acquisition, which is expected to close in the summer of 2025.
Price Action: CAL shares are down 2.46% at $15.99 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44414695/temu-parent-pdd-holdings-drops-after-q4-revenue-miss-details" target="_blank" rel="noreferrer noopener">Temu Parent PDD Holdings Drops After Q4 Revenue Miss: Details</a></li>
</ul>
Image via Shutterstock.

Small Cap

Caleres Reports Lower Q4 Sales, Cautious Outlook For 2025 Amid Inflation And Tariffs

Pure Storage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) short percent of float has fallen 22.35% since its last report. The company recently reported that it has 9.16 million shares sold short, which is 3.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Pure Storage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484630_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pure Storage has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Pure Storage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Pure Storage's peer group average for short interest as a percentage of float is 8.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PSTG

Is Pure Storage Gaining or Losing Market Support?

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Abbott Laboratories?

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 19.16% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484619_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.07%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Penumbra's Recent Short Interest

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 15.88%. Currently, UnitedHealth Group has a market capitalization of $465.40 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $4,307.40 today based on a price of $508.79 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

OmniAb

Noticias

Últimas noticias sobre OmniAb (NASDAQ:OABI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL